Beijing Beilu Pharmaceutical Hits Day High with 7.32% Surge

Beijing Beilu Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 7.32% on March 6, 2026. The stock reached an intraday high of CNY 11.36, reflecting strong market activity. Over the past year, the company has delivered impressive returns of 49.86%, significantly outperforming the China Shanghai Composite, which recorded a gain of 21.98% during the same period. In terms of financial metrics, Beijing Beilu has shown robust growth in net sales, which reached CNY 872.68 million, marking a 21.13% increase. The company also reported a net profit of CNY 25.38 million for the half-year, indicating a positive trajectory. Despite a high price-to-earnings ratio of 309.00, the stock's performance has been bolstered by a solid dividend yield of 0.61%. The company's market capitalization stands at CNY 4,001 million, positioning it as a mid-cap player in the pharmaceuticals and biotechnology sector. With a return on equity of 0.67% and a debt-to-equity ratio of -0.06, Beijing Beilu continues to demonstrate resilience in a competitive market landscape.